O'Shaughnessy Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

O'Shaughnessy Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,474	Closed	-$266K	–	2636
2025 Q3	$266K	Buy	+12,474	New	+$295K	﹤0.01%	1812
2021 Q4	–	Sell	-261	Closed	-$4K	–	1261
2021 Q3	$4K	Hold	261	–	–	﹤0.01%	2357
2021 Q2	$6K	Hold	261	–	–	﹤0.01%	2094
2021 Q1	$7K	Hold	261	–	–	﹤0.01%	1841
2020 Q4	$14K	Hold	261	–	–	﹤0.01%	1474
2020 Q3	$11K	Hold	261	–	–	﹤0.01%	1328
2020 Q2	$13K	Buy	+261	New	+$12.5K	﹤0.01%	1206
2020 Q1	–	Sell	-355	Closed	-$15K	–	1270
2019 Q4	$15K	Buy	+355	New	+$15.4K	﹤0.01%	1199

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

O'Shaughnessy Asset Management's ACAD Position: Q4 2025 in Review

O'Shaughnessy Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 12,474 shares — an estimated $266K sold.

O'Shaughnessy Asset Management first reported a position in ACAD in Q4 2019 and held it in 8 quarters. The position peaked at $266K in Q3 2025. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

O'Shaughnessy Asset Management reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
O'Shaughnessy Asset Management sold 12,474 Acadia Pharmaceuticals shares in Q4 2025, an estimated $266K.
O'Shaughnessy Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 8 quarters.
O'Shaughnessy Asset Management's Acadia Pharmaceuticals position peaked at $266K in Q3 2025.
336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.